Objective:

To identify a previously underrecognized subset of lung cancers with aggressive neuroendocrine-like biology.

Approach:

• Study Design: Analysis of DNA and RNA sequencing data from 49,144 lung cancer samples using the Caris Life Sciences database.
• Transcriptomic Profiling: Development of a transcriptomic 'HGNEC activity score' to identify tumors with aggressive neuroendocrine-like biology.

Key Findings:

• HGNEC-like tumors represent about 3-6% of NSCLC cases.
• These tumors are associated with significantly shorter overall survival.
• They are more likely to spread to lymph nodes and the brain.
• HGNEC-like tumors are biologically aggressive and resemble small cell lung cancers.
• They often lack PD-L1 expression, a marker for immunotherapy response.
• High levels of neuroendocrine markers such as DLL-3 are present, which are targetable with specific therapies.
• These tumors carry molecular alterations commonly associated with neuroendocrine cancers such as SCLC, including abnormalities in TP53 and RB1.

Interpretation:

The study suggests that advanced molecular testing could help identify high-risk tumors and personalize treatment strategies.

Limitations:

• The study may not capture all biological differences due to reliance on existing pathology classifications.
• The clinical significance of the findings needs further validation in larger cohorts.

Conclusion:

Advanced molecular profiling may improve patient selection for clinical trials and treatment strategies based on tumor biology.

Sources:

• Fox Chase Cancer Center